News
Headlines

Seattle BioMed and Yecuris Team Up to Identify Novel Vaccine and Drug Candidates for Malaria

02-Jun-2014. Seattle BioMed and Yecuris Team Up to Identify Novel Vaccine and Drug Candidates for Malaria Date: Mon, 06/02/2014 Seattle BioMed and the Yecuris C..

Yecuris offers MetAbArrayâ„¢ In-Cell Proteomics Screening

17-Mar-2014. Yecuris™exclusively licenses the rights to offer the novel in-cell proteomics method known as the MetAbArray™ for in vitro and in vivo compound screening for toxicity and metabolism as..

*HOT* New Publications

26-Feb-2014. Two recent Nature articles have been published utilizing Yecuris™ FRG KO technology. Both articles are groundbreaking uses for humanized animal technology and we're proud to be a part of th..

2014 SOT Appearance

04-Feb-2014. Yecuris will be in attendance at the 2014 SOT meeting in Phoenix, Arizona from March 24th to March 27th. We will be attending the meeting with our distribution and marketing partner, Taconic at b..

Yecuris and Kurabo Sign Distribution Deal for Japan

15-Jan-2014. We are proud to announce that as of January 1st, 2014, Kurabo Bio-Medical will be the exclusive distributor of the FRG® KO mouse technology in Japan. For more information on Kurabo and their ..

Taconic and Yecuris Corporation Announce Strategic Marketing Alliance

22-Feb-2013. Taconic and Yecuris Corporation Announce Strategic Marketing Alliance Taconic to distribute Yecuris Corporation human xenograft FRG™ KO mouse technologies in the US and Europe Huds..

Select Metabolism Data

04-Apr-2012. SELECT IN VITRO METABOLISM DATA Human cells isolated from FRG® KO animals have been extensively characterized for phase I and II metabolism, transport, and induction. All analysis has be..